These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36292123)

  • 1. Is Omalizumab Related to Ear and Labyrinth Disorders? A Disproportionality Analysis Based on a Global Pharmacovigilance Database.
    Park HT; Park S; Jung YW; Choi SA
    Diagnostics (Basel); 2022 Oct; 12(10):. PubMed ID: 36292123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
    Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
    BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A risk of serious anaphylatic reactions to asthma biologics: a pharmacovigilance study based on a global real-world database.
    Park S; Kim Y; Lee GH; Choi SA
    Sci Rep; 2023 Oct; 13(1):17607. PubMed ID: 37848636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short communication: Comments on hair disorders associated with dupilumab based on VigiBase.
    Park S; Park SH; Byun YJ; Choi SA
    PLoS One; 2022; 17(7):e0270906. PubMed ID: 35895603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.
    Li L; Wang Z; Cui L; Xu Y; Guan K; Zhao B
    Clin Transl Allergy; 2021 Jun; 11(4):e12038. PubMed ID: 34123366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologics for asthma and risk of pneumonia.
    Matera MG; Ora J; Calzetta L; Rogliani P; Cazzola M
    J Asthma; 2024 Sep; 61(9):905-911. PubMed ID: 38294705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration's adverse event reporting system (FAERS).
    Pera V; Brusselle GG; Riemann S; Kors JA; Van Mulligen EM; Parry R; de Wilde M; Rijnbeek PR; Verhamme KMC
    Front Pharmacol; 2023; 14():1276340. PubMed ID: 38035014
    [No Abstract]   [Full Text] [Related]  

  • 9. Characterizing Adverse Events of Biologic Treatment of T2 Disease: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Stack TJ; Kim S; Lamb MM; Mohammad I; Zeatoun A; Lopez E; Klatt-Cromwell C; Thorp BD; Ebert CS; Senior BA; Kimple AJ; Alicea D
    ORL J Otorhinolaryngol Relat Spec; 2023; 85(6):329-339. PubMed ID: 37963438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment.
    Davison J; Doe S
    Respir Med Case Rep; 2021; 34():101557. PubMed ID: 34877251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of patients with severe asthma who experienced treatment failure with omalizumab.
    Akaba T; Kondo M; Kobayashi F; Honda N; Muramatsu S; Yagi O; Takeyama K; Seo Y; Nonaka M; Tagaya E
    Pulm Pharmacol Ther; 2021 Jun; 68():102032. PubMed ID: 33862220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases.
    Jackson K; Bahna SL
    Expert Rev Clin Immunol; 2020 Mar; 16(3):311-319. PubMed ID: 31994421
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of Biologics on Refractory Eosinophilic Otitis Media Associated with Bronchial Asthma or Severe Uncontrolled CRSwNP.
    De Corso E; Montuori C; Settimi S; Mele DA; Cantiani A; Corbò M; Cantone E; Paludetti G; Galli J
    J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
    Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID
    Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologics for eosinophilic otitis media: a retrospective case study in a multidisciplinary center.
    Czajkowski M; Machiels S; Leclercq C; Poirrier AL; Schleich F; Louis R; Dezfoulian B; Lefebvre P; Defaweux V; Camby S; Rogister F
    Eur Arch Otorhinolaryngol; 2024 Sep; ():. PubMed ID: 39271591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Monoclonal Antibodies for Treatment of Uncontrolled Eosinophilic Asthma.
    Koski RR; Grzegorczyk KM
    J Pharm Pract; 2020 Aug; 33(4):513-522. PubMed ID: 31046541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: Real-world US ADVANTAGE study.
    Bleecker E; Blaiss M; Jacob-Nara J; Huynh L; Duh MS; Guo T; Ye M; Stanford RH; Wang Z; Soler X; Nag A; Nair R; Borsos K
    J Allergy Clin Immunol; 2024 Aug; ():. PubMed ID: 39186985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological therapy-associated adverse reactions in asthma: analysis of reporting to the Portuguese pharmacovigilance system.
    Sousa J; Taborda-Barata L; Monteiro C
    Expert Opin Drug Saf; 2020 Jan; 19(1):99-106. PubMed ID: 31661986
    [No Abstract]   [Full Text] [Related]  

  • 20. Real-world benefits of biologics for asthma: Exacerbation events and systemic corticosteroid use.
    Kimura Y; Suzukawa M; Inoue N; Imai S; Akazawa M; Matsui H
    World Allergy Organ J; 2021 Nov; 14(11):100600. PubMed ID: 34820049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.